Welcome to our dedicated page for InMed Pharmaceuticals SEC filings (Ticker: INM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
InMed Pharmaceuticals Inc. filings document the regulatory record of a British Columbia pharmaceutical issuer with common shares listed on Nasdaq under INM. Its disclosures cover small-molecule drug development programs targeting CB1 and CB2 receptors, including INM-901 for Alzheimer's disease and programs in ocular and dermatological indications.
Recent filings include Current Reports on Form 8-K for financial results and business updates, material definitive agreements involving preferred investment options, at-the-market offering documentation, Nasdaq continued-listing compliance, shareholder voting matters, and exit or disposal activities related to BayMedica. The company's formal reports also address risk factors, capital structure, governance, and clinical or regulatory disclosures.
InMed Pharmaceuticals Inc. plans to acquire 100% of Mentari Therapeutics, Inc. through a reverse triangular merger, after which Mentari will become a wholly owned subsidiary and then merge into another InMed subsidiary. The transaction is intended to be tax-free.
Post-closing, InMed holders are expected to own about 1.15% of the combined company, Mentari holders about 22.63%, an initial private placement about 52.51% and a second private placement about 23.70%, implying a total transaction value of roughly $621 million. Concurrent financings include a $290 million initial tranche and a $200 million second tranche, both closing immediately before the merger.
An estimated 601,195,812 shares of common stock of the combined company will be outstanding on an as-converted/as-exercised basis, including 6,926,398 InMed shares representing 1.15%. Proceeds are expected to fund Mentari’s migraine-prevention pipeline (programs MT-001, MT-002, MT-003 and others) with anticipated Phase 1 and Phase 2a data and a projected cash runway into 2029. Closing is subject to shareholder approvals, Form S-4 effectiveness, Nasdaq listing and other customary conditions, with management and the board to be led by Mentari. Key insiders will be subject to a 180-day lock-up.
InMed Pharmaceuticals Inc. describes an amendment to Mentari Therapeutics’ pre-closing financing tied to their pending merger. On July 22, 2026, Mentari and certain original and new investors agreed to purchase an additional $200 million of common stock and/or pre-funded warrants immediately before the first merger effective time.
The purchase price for the additional shares equals 152.80% of the price paid by original investors, with additional pre-funded warrants priced at that amount minus $0.0001. The expanded financing is expected to extend Mentari’s cash runway into 2029 and support Phase 2a readouts for two PACAP-targeted migraine programs, including MT-002. Based on the merger exchange ratio, pre‑merger Mentari stockholders are expected to own about 98.85% of the combined company and pre‑merger InMed shareholders about 1.15%, with approximately 601,195,812 common shares outstanding on an as-converted / as-exercised basis after completion.
InMed Pharmaceuticals describes an amendment to Mentari Therapeutics’ pre-closing financing tied to their pending merger. Under Amendment No. 1 to the Securities Purchase Agreement, certain original and new investors agreed to purchase an additional $200 million of Mentari common stock and pre-funded warrants immediately prior to the first merger effective time.
The Additional Shares are priced at 152.80% of the per-share price paid by the original investors, with pre-funded warrants priced at that amount minus $0.0001. This expanded Pre-Closing Financing is expected to extend Mentari’s cash runway into 2029, through Phase 2a readouts for its two PACAP-targeted lead migraine programs, and to support its broader migraine prevention pipeline. Based on the merger exchange ratio, pre-Merger Mentari stockholders are expected to own approximately 98.85% of the combined company and pre-Merger InMed shareholders about 1.15%, with total as-converted and as-exercised common shares around 601,195,812.
InMed Pharmaceuticals Inc. describes a proposed merger with Mentari Therapeutics, under which two InMed merger subsidiaries will combine with Mentari in a two-step structure, leaving an InMed subsidiary as the surviving entity. Completion is subject to conditions in the Merger Agreement, including shareholder approvals and effectiveness of a Form S-4 registration statement.
Mentari has appointed Greg Divis, former Avadel Pharmaceuticals CEO, as Chief Executive Officer and board member, effective July 20, 2026. Mentari is developing migraine-prevention therapies MT-001, an anti-PACAP antibody, and MT-002, an anti-PACAP/anti-CGRP bispecific antibody, with regulatory filings planned in MY 2026 and Q1 2027, respectively. Extensive forward-looking statements language highlights risks such as failure to close the merger, financing risks, redomestication and reverse stock split steps, and Nasdaq continued-listing requirements.
Private investment funds managed by ADAR1 Capital Management, LLC, a ten percent owner of InMed Pharmaceuticals, purchased 1,000 Common Shares on July 15, 2026 at $1.555 per share, increasing their indirect holdings to 801,000 shares. ADAR1 and Daniel Schneeberger may be deemed indirect owners but each disclaims beneficial ownership except for any pecuniary interest. The transaction was not marked as pursuant to a Rule 10b5-1 trading plan.
Vivo Opportunity–affiliated entities reported open-market purchases totaling 20,546 Common Shares of InMed Pharmaceuticals Inc. at $1.55 per share on July 14–16, 2026. The trades, made through Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P., brought their holdings to 743,057 and 75,019 shares, respectively. Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC, as general partners, disclaim beneficial ownership beyond their pecuniary interests.
InMed Pharmaceuticals Inc. entered into Amendment No. 1 to its Agreement and Plan of Merger and Reorganization with Mentari Therapeutics, Inc. and two merger subsidiaries. The amendment clarifies the sequence of corporate actions, including a planned name change to “Mentari Therapeutics, Inc.” before closing, a redomestication from British Columbia to Nevada on the closing date before filing the certificate of merger, and any Nasdaq reverse split before the first merger effective time. It introduces a defined Company PIPE Amendment to enable potential additional pre-closing private placement financing for Mentari and clarifies how such financing affects the exchange ratio. It also confirms the combined mergers are intended to qualify as a tax “reorganization” under Section 368(a) of the Internal Revenue Code and removes a prior contingency about a possible Cayman redomestication. InMed and Mentari also announced that a Form S-4 with a preliminary joint proxy statement/prospectus has been filed with the SEC.
InMed Pharmaceuticals Inc. entered into Amendment No. 1 to its Agreement and Plan of Merger and Reorganization with Mentari Therapeutics, refining key aspects of their previously announced all‑stock business combination. The amendment clarifies the sequencing of the contemplated steps, including that InMed will change its name to “Mentari Therapeutics, Inc.” before closing, redomesticate from British Columbia to Nevada on the closing date but before the merger is filed, and complete any required Nasdaq reverse split before the first merger effective time.
The amendment also introduces a defined Company PIPE Amendment to allow potential additional pre‑closing private placement financing for Mentari and sets out how such financing would affect the exchange ratio between the parties. In addition, it confirms the intended U.S. tax treatment, stating that the two merger steps are expected to form a single “reorganization” under Section 368(a) of the Internal Revenue Code, and removes a prior contingency regarding a possible redomestication to the Cayman Islands.
Separately, InMed filed a registration statement on Form S‑4 on July 2, 2026 containing a preliminary joint proxy statement/prospectus and management information circular for the proposed transaction, which has board approval at both companies and is targeted to close in the fourth quarter of 2026, subject to shareholder approvals, effectiveness of the Form S‑4 and other customary conditions.
InMed Pharmaceuticals Inc. reported that investment entities affiliated with Vivo Opportunity made a series of open-market purchases of its Common Shares. Over June 30 to July 2, 2026, Vivo Opportunity Cayman Fund, L.P. and Vivo Opportunity Fund Holdings, L.P. together bought 6,551 shares at weighted average prices around $1.54–$1.55 per share in multiple transactions within stated price ranges. Following these purchases, Cayman Fund indirectly held 73,135 shares and Fund Holdings indirectly held 724,395 shares, with general partners Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC disclaiming beneficial ownership except for their pecuniary interest.
InMed Pharmaceuticals Inc. files a preliminary proxy statement/prospectus on Form S-4 to register securities in connection with a proposed merger with Mentari Therapeutics, Inc. The filing discloses an estimated Exchange Ratio of approximately 2.0606 InMed Common Shares per share of Mentari Common Stock (based on specified capitalization and an assumed InMed net cash at closing of $(3.6) million). Mentari entered into a Mentari Pre-Closing Financing for approximately $290.0 million.
Post-closing ownership is currently projected to be ~1.51% for pre-merger InMed securityholders and ~98.49% for former Mentari securityholders on a fully-diluted basis, subject to adjustments described in the Merger Agreement. The transaction contemplates a redomestication to Nevada, a proposed name change to Mentari Therapeutics, Inc., an anticipated Nasdaq ticker of MTRI, a proposed Reverse Stock Split, and issuance of Contingent Value Rights with a primary term to the second anniversary (extendable as described). Completion is conditioned on customary closing items, including Nasdaq confirmation of listing.